Analysts Issue Forecasts for UBX Q1 Earnings

Unity Biotechnology, Inc. (NASDAQ:UBX) – Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for Unity Biotechnology in a research note issued to investors on Monday, March 10th. HC Wainwright analyst M. Caufield expects that the company will post earnings per share of ($0.43) for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Unity Biotechnology’s Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS and FY2029 earnings at $0.88 EPS.

Separately, Chardan Capital reiterated a “buy” rating and issued a $6.00 price target on shares of Unity Biotechnology in a research note on Monday.

Unity Biotechnology Stock Up 7.5 %

Shares of Unity Biotechnology stock opened at $1.72 on Tuesday. Unity Biotechnology has a 52-week low of $0.94 and a 52-week high of $3.10. The company has a 50 day moving average of $1.87 and a 200 day moving average of $1.51. The company has a market capitalization of $28.98 million, a P/E ratio of -1.31 and a beta of 1.02.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Unity Biotechnology stock. Bridgeway Capital Management LLC lifted its stake in shares of Unity Biotechnology, Inc. (NASDAQ:UBX) by 100.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 50,000 shares of the company’s stock after buying an additional 25,000 shares during the quarter. Bridgeway Capital Management LLC owned about 0.30% of Unity Biotechnology worth $49,000 at the end of the most recent reporting period. 29.49% of the stock is owned by institutional investors.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.